As California continues to be a key player in the health care industry, pharmaceutical and medical device companies in the state are finding themselves increasingly susceptible to the federal government's crackdown on corruption in the industry. The U.S. Department of Justice has been aggressively enforcing the Foreign Corrupt Practices Act (FCPA), a federal anti-bribery statute that prohibits the exchange of money for business. Enforcement of the statute has been focused on the health care industry, particularly pharmaceutical and medical device companies. Thomas W. McNamara, managing partner in Ballard Spahr's San Diego office, examined the issues in an article he penned for the Daily Journal.